These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 29883463)

  • 1. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
    Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
    PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
    Tsukahara K; Kubota A; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Fukushima M; Teramukai S; Fujii M;
    PLoS One; 2015; 10(2):e0116965. PubMed ID: 25671770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
    Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
    Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
    Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
    Tsukuda M; Kida A; Fujii M; Kono N; Yoshihara T; Hasegawa Y; Sugita M;
    Br J Cancer; 2005 Oct; 93(8):884-9. PubMed ID: 16189518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():172-8. PubMed ID: 16897997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Miyakita H; Ogimi T; Nagase H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1077-1085. PubMed ID: 28417167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
    Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
    Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
    Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
    Yoshida M; Ishiguro M; Ikejiri K; Mochizuki I; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Nakatani E; Sugihara K;
    Ann Oncol; 2014 Sep; 25(9):1743-1749. PubMed ID: 24942277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
    Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
    Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
    Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
    Kim HR; Lee CG; Choi EC; Kim JH; Koh YW; Cho BC
    Head Neck; 2016 Apr; 38 Suppl 1():E1653-9. PubMed ID: 26890965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
    Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
    PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.
    Furusaka T; Tanaka A; Matsuda H; Ikeda M
    Acta Otolaryngol; 2011 Oct; 131(10):1099-103. PubMed ID: 21651316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.